TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34158317

Group type: EXPERIMENTAL
Intervention: R2-GDP treatment (rituximab, gemcitabine, dexamethasone, and cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R2-GDP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study: 33002429

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Salvage radiotherapy
Number of subjects: 1396
Study: 33621983

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: N‐BiPAP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 120
Study: 33373678

Group type: EXPERIMENTAL
Intervention: Regular coffee (200 mg caffeine at breakfast and 100 mg caffeine after lunch)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 26
Study: 35418281

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal saline (control group, n = 24)
Number of subjects: 47
Study: 32301668

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with 808 nm wavelength, 50 mW power, continuous mode emission, 4 J/cm2 dosimetry, administered daily for 10 consecutive days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14
Study: 36284342

Group type: EXPERIMENTAL
Intervention: EX + 60 °C (carbohydrate-protein-containing drink at 60 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: EX + 4 °C (carbohydrate-protein-containing drink at 4 °C)
Number of subjects: 12
Study: 33598741

Group type: COMPARATOR
Intervention: High‐to‐low (Webster's triangle preservation) osteotomy (control group, n = 23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low‐to‐low osteotomy (study group, n = 23)
Number of subjects: 46
Study: 32384495

Group type: EXPERIMENTAL
Intervention: Improved method of finding recurrent laryngeal nerve (lateral approach)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control method of finding recurrent laryngeal nerve (blunt separation)
Number of subjects: 158
Study: 35064992

Group type: EXPERIMENTAL
Intervention: Fentanyl with ketamine and rocuronium
Number of subjects: 290

Group type: COMPARATOR
Intervention: 0.9% saline (placebo) with ketamine and rocuronium
Number of subjects: 290
Study: 33504039

Group type: EXPERIMENTAL
Intervention: PRPA diagnosis
Number of subjects: 5779
Study: 35351048

Group type: EXPERIMENTAL
Intervention: Iconic therapy (IT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychological supportive intervention (SI)
Number of subjects: 40
Study: 33813246

Group type: EXPERIMENTAL
Intervention: Computerized Atlanta Protocol (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paper-based Joint British Diabetes Societies For Inpatient Care Protocol (Group II)
Number of subjects: 100
Study: 35577391

Group type: EXPERIMENTAL
Intervention: Scent dogs trained to detect COVID-19 using skin swabs
Number of subjects: 420
Study: 33773631

Group type: EXPERIMENTAL
Intervention: β‐lactam treatment (oral amoxicillin 1 g plus clavulanate 125 mg three times a day for 5 extra days)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo (matched placebo for 5 extra days)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: β‐lactam treatment
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 36063595

Group type: EXPERIMENTAL
Intervention: Conflict in evidence
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Conflict between two expert sources
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Conflict within the same expert source
Number of subjects: 1027

Group type: COMPARATOR
Intervention: No conflict control
Number of subjects: 1027
Study: 32777193

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (2 mg/kg/day) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (2 mg/kg/day) plus budesonide nebulization (0.5 mg every 12 h)
Number of subjects: 0
Study: 35105318

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 1545
Study: 32093137

Group type: EXPERIMENTAL
Intervention: A‐F Betafood®
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (A‐F Betafood® and Placebo)
Number of subjects: 50
Study: 34791074

Group type: EXPERIMENTAL
Intervention: Fosfomycin (3 gr once daily for 10 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ciprofloxacin (0.5 gr twice daily for 10 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 97
Study: 32070923

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin, fluorouracil, and docetaxel (TPF)
Number of subjects: 0
Study: 35193470

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 95
Study: 33165148

Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Clothing
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Health care
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Utilities
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Debts
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Housing
Number of subjects: 295
Study: 35902297

Group type: EXPERIMENTAL
Intervention: Paclitaxel 65 mg/m2 plus pazopanib 600–800 mg daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard weekly paclitaxel 80 mg/m2
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combination therapy (Paclitaxel plus pazopanib)
Number of subjects: 116
Study: 32923171

Group type: EXPERIMENTAL
Intervention: Tecemotide
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 35462214

Group type: EXPERIMENTAL
Intervention: Plantar vibration therapy at 80Hz and conventional physical therapy (CPT) for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plantar vibration therapy at 80Hz and CPT for 4 weeks
Number of subjects: 30
Study: 33368766

Group type: EXPERIMENTAL
Intervention: STAR mapping guided ablation (PVI plus STAR mapping)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional ablation (PVI plus CFAE/linear ablation)
Number of subjects: 130

Group type: COMPARATOR
Intervention: PVI alone ablation
Number of subjects: 130
Study: 35079813

Group type: EXPERIMENTAL
Intervention: Nurse-led, screening-triggered early specialized palliative care intervention programme (questionnaire-based screening and advanced-level nurse counselling)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nurse-led, screening-triggered early specialized palliative care intervention programme
Number of subjects: 50
Study: 32873750

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 100

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 100
Study: 34402133

Group type: EXPERIMENTAL
Intervention: AA-OT program plus treatment as usual
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 16
Study: 35642747

Group type: EXPERIMENTAL
Intervention: VDZ/PTX
Number of subjects: 30

Group type: COMPARATOR
Intervention: VDZ
Number of subjects: 30
Study: 32978424

Group type: EXPERIMENTAL
Intervention: Breast-fed
Number of subjects: 91

Group type: COMPARATOR
Intervention: Formula A
Number of subjects: 91

Group type: COMPARATOR
Intervention: Formula B
Number of subjects: 91
Study: 37950162

Group type: COMPARATOR
Intervention: Diphereline 11.25 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Microrelin 11.25 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Microrelin 3.75 mg
Number of subjects: 133
Study: 34361118

Group type: EXPERIMENTAL
Intervention: Quantitative Structure‐Activity Relationship (QSAR) model
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: QSAR analysis
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: QSAR model validation
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Analysis of crystal structures
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Identification of pharmacophoric features
Number of subjects: 1121
Study: 32686240

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of structured Respecting Choices interviews
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conversations initiated by providers about living well
Number of subjects: 30
Study: 35713906

Group type: EXPERIMENTAL
Intervention: Culturally tailored PCP outreach
Number of subjects: 8287

Group type: EXPERIMENTAL
Intervention: Standard PCP outreach
Number of subjects: 8287

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8287
Study: 34549648

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tai-chi
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-management control
Number of subjects: 30
Study: 32613714

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT; scaling and root planing plus azithromycin 500 mg every day for 3 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Minimal periodontal treatment (MPT; supragingival professional mechanical plaque removal plus a placebo)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT)
Number of subjects: 63
Study: 35578568

Group type: EXPERIMENTAL
Intervention: Resmon Pro Full (8 Hz)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Resmon Pro Full (5‐11‐19 Hz)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: tremoflo C‐100 (5–37 Hz)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: tremoflo C‐100 (7–41 Hz)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Device-specific reference equations derived
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Standing height
Number of subjects: 306
Study: 33714745

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 32544852

Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD) with adjunctive prebiotic, probiotic, or synbiotic
Number of subjects: 20
Study: 34034256

Group type: EXPERIMENTAL
Intervention: AREDS2 dietary supplementation for 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no AREDS2 supplementation)
Number of subjects: 62
Study: 34511165

Group type: EXPERIMENTAL
Intervention: Parent-child painting and creative crafting therapy in addition to applied behavior analytic intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Applied behavior analytic intervention (Control)
Number of subjects: 56
Study: 36244667

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) supplementation (0.6 μg/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no DEX supplementation)
Number of subjects: 96
Study: 32942327

Group type: EXPERIMENTAL
Intervention: 24% sucrose plus pacifier
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pacifier
Number of subjects: 32
Study: 32297407

Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 17
Study: 35941763

Group type: EXPERIMENTAL
Intervention: Educational intervention on NSSI
Number of subjects: 23
Study: 34415933

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART) containing tenofovir/emtricitabine plus lopinavir/ritonavir
Number of subjects: 2444

Group type: COMPARATOR
Intervention: Infant Nevirapine prophylaxis (iNVP)
Number of subjects: 2444

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART)
Number of subjects: 2444
Study: 34323337

Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum extract (ActivAMP®)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 33989311

Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in single-gender nonmajor biology groups
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in mixed-gender groups for major and nonmajor sections
Number of subjects: 440

Group type: COMPARATOR
Intervention: Traditional Lecture-based Learning (TL)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in single-gender groups
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL) in mixed-gender groups
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Collaborative Learning (CL)
Number of subjects: 440
Study: 32501596

Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention including four face-to-face sessions with a school nurse over 5 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard school healthcare (control group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention
Number of subjects: 98
Study: 35428822

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 1561
Study: 32800511

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 881

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study: 35416909

Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose triple combination pill (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) therapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose triple combination pill
Number of subjects: 700
Study: 34259405

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment by stages, once every other day, 3 times a week for 3 menstrual cycles.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Femoston (estradiol tablets/estradiol and dydrogesterone tablets, 1 tablet per day) for 3 menstrual cycles.
Number of subjects: 66
Study: 33964254

Group type: EXPERIMENTAL
Intervention: Primary lung resection before systemic treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Primary lung resection after systemic treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-organ metastasis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nonsolitary metastasis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 33879218

Group type: EXPERIMENTAL
Intervention: Curcumin (80 mg based on body surface)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34339111

Group type: EXPERIMENTAL
Intervention: Exercise (70% VO2 max to expend 400 kcal)
Number of subjects: 12
Study: 35485238

Group type: EXPERIMENTAL
Intervention: Capnography with Integrated Pulmonary Index enabled
Number of subjects: 400

Group type: COMPARATOR
Intervention: Capnography alone
Number of subjects: 400
Study: 33892677

Group type: EXPERIMENTAL
Intervention: Counseling (4 sessions of 60 minutes each)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no counseling)
Number of subjects: 102
Study: 33165218

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (audio recording)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control (heart rate monitor)
Number of subjects: 50
Study: 33256379

Group type: EXPERIMENTAL
Intervention: R-CHOP plus lenalidomide (R2CHOP)
Number of subjects: 82
Study: 35166150

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (90 units injected in 18 sites over cranial sutures)
Number of subjects: 19
Study: 34450216

Group type: EXPERIMENTAL
Intervention: TT-TG distance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TT-TG distance/TW
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TT-TG distance/TDI
Number of subjects: 48
Study: 36154752

Group type: EXPERIMENTAL
Intervention: Intervention group 2 (12-session intervention program + glucometer and accessories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 0
Study: 34982021

Group type: COMPARATOR
Intervention: 1TRS (one resistance training session involving eight sets of 10 reps at 70% of 1RM at the bench press)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2TRS (two resistance training sessions with a recovery time of 4 hr, same total volume as 1TRS)
Number of subjects: 24
Study: 33852651

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) at 1-3 days after ERCP (OG)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) at 4-7 days after ERCP (CG)
Number of subjects: 103
Study: 32500636

Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg) given as a 6-hour infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glenzocimab
Number of subjects: 0
Study: 36163070

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 17
Study: 33875372

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) combined with cognitive training
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: tACS (5 Hz) combined with cognitive training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham stimulation combined with cognitive training
Number of subjects: 59
Study: 33792409

Group type: EXPERIMENTAL
Intervention: Side-lying sleep position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine sleep position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ETCO2 monitoring
Number of subjects: 30
Study: 33913192

Group type: EXPERIMENTAL
Intervention: 5‐min mindfulness of love
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5‐min supportive listening
Number of subjects: 60
Study: 35323950

Group type: EXPERIMENTAL
Intervention: Aspirin use within the first day of hospitalization
Number of subjects: 112269
Study: 33092479

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Popular music
Number of subjects: 100
Study: 32665059

Group type: EXPERIMENTAL
Intervention: RM followed by individualised PEEP (RM/PEEPIND) optimised using electrical impedance tomography
Number of subjects: 40

Group type: COMPARATOR
Intervention: No RM with 5 cm H2O PEEP
Number of subjects: 40
Study: 33654149

Group type: EXPERIMENTAL
Intervention: Titanium cable plus locking plate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 36
Study: 35396924

Group type: EXPERIMENTAL
Intervention: 10-mg generic domperidone tablet (test)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Branded domperidone tablet (reference)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 10-mg generic domperidone tablet (test) in fed state
Number of subjects: 96

Group type: COMPARATOR
Intervention: Branded domperidone tablet (reference) in fed state
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Comparison of fasting and fed states
Number of subjects: 96
Study: 34620933

Group type: EXPERIMENTAL
Intervention: 3×/week progressive aerobic training (AT) for 6 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Education program (CON)
Number of subjects: 71
Study: 32174573

Group type: EXPERIMENTAL
Intervention: Scheimpflug imaging (Group II)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Slit lamp marking only (Group I)
Number of subjects: 2
Study: 36376341

Group type: EXPERIMENTAL
Intervention: Probiotic fermented dairy food (N=74)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo fermented dairy food (N=79)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual diet (N=98)
Number of subjects: 251
Study: 32449311

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with failed or incomplete recanalization (TICI 0–2b)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with failed recanalization (TICI 0–2a)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Best medical treatment only
Number of subjects: 170
Study: 35862280

Group type: EXPERIMENTAL
Intervention: Hearing-aid amplification with active occlusion cancellation in quiet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hearing-aid amplification with active occlusion cancellation in noise (70 dB SPL babble noise)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No hearing-aid amplification in noise (70 dB SPL babble noise)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No hearing-aid amplification in quiet
Number of subjects: 22
Study: 33784598

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 250
Study: 34247660

Group type: EXPERIMENTAL
Intervention: Internet intervention (n = 201)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Informational control group (n = 202)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 403
Study: 33945439

Group type: EXPERIMENTAL
Intervention: One booster dose of Kanghua HDCV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two booster doses of Kanghua HDCV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kanghua HDCV (no booster)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pasteur group (no booster)
Number of subjects: 0
Study: 33109288

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) using breath-holding to simulate lung pathology
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) using ultrasound (US) simulation software
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lung ultrasound (LUS) while parked
Number of subjects: 17
Study: 33661675

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT), mean of 15 sessions over 25 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 20
Study: 32079447

Group type: EXPERIMENTAL
Intervention: Disinsertion of rectus muscles
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Moderate to severe restriction on forced duction testing (FDT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Longer limbal-insertion distance (LID) before disinsertion
Number of subjects: 110